Nexus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEXUS, and what generic alternatives to NEXUS drugs are available?
NEXUS has twenty-one approved drugs.
There are five US patents protecting NEXUS drugs.
There are ten patent family members on NEXUS drugs in nine countries and eighty-eight supplementary protection certificates in nine countries.
Summary for Nexus
| International Patents: | 10 |
| US Patents: | 5 |
| Tradenames: | 23 |
| Ingredients: | 20 |
| NDAs: | 21 |
Drugs and US Patents for Nexus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus | POTASSIUM CHLORIDE 20MEQ | potassium chloride | INJECTABLE;INJECTION | 214727-003 | Mar 18, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nexus | POTASSIUM CHLORIDE 20MEQ | potassium chloride | INJECTABLE;INJECTION | 214727-004 | Mar 18, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nexus | ISOPROTERENOL HYDROCHLORIDE | isoproterenol hydrochloride | INJECTABLE;INJECTION | 206961-001 | Aug 2, 2017 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Drugs
Supplementary Protection Certificates for Nexus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0268956 | SPC/GB98/040 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508 |
| 1856135 | CR 2020 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
